Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) opened at $17.8, and ended 7.04% higher at $19. Nearly 1.87 million shares were traded by the close, higher than its average daily volume of 1.14 million shares.Abeona Therapeutics Inc. (ABEO) Analyst Opinion
Abeona Therapeutics Inc. has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 23.19% of shares outstanding. The stock spiked 17.28% last month and is up 291.75 this year. Wall Street is only getting more bullish on the stock, with 7 of analysts who cover ABEO having a buy-equivalent rating. Analysts have placed a $26.14 price target on Abeona Therapeutics Inc., suggesting a 37.58% gain from recent close. It’s currently trading about -16.48% below its 52-week high.
Abeona Therapeutics Inc. (ABEO) failed to surprise the stock market in its last reported earnings when it earned -$0.21 a piece versus the consensus-estimated -$0.15. Its revenue totaled $230000 up 21.05% from the previous quarter.Abeona Therapeutics Inc. (NASDAQ:ABEO) Intraday View
This stock (ABEO) is ahead of its 52-week low with 369.14%. Its last month’s stock price volatility remained 8.64% which for the week stands at 10.52%. The share price has moved forward from its 20 days moving average, trading at a distance of 11.05% and stays 36.48% away from its 50 days moving average. Over the last five days, shares have managed 18.01% gains and now is up 140.54% since hitting its 200-day moving average of $9.17. Abeona Therapeutics Inc. (ABEO) has made its way to a 12-month gain of 118.39%.
Turning to ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), its shares were trading at $5.4 a retreat of $-0.23, on the trading floor. The stock, after opening at $5.65, touched a high of $5.65 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.5. ZIOPHARM Oncology, Inc. has 1 buy ratings, 4 holds and 0 sells even after the stock tumbled -31.47% from its high of $ 7.88 to a $787.32 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 2.5 to 2.5 during a month. Analysts set a 12-month price target of $12.5 a share. The target implies a 131.48% spike from where the shares are currently trading. Also, the current price highlights a discount of 325.93% to analysts’ high consensus price target.ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Intraday Trading
The counter witnessed a trading volume of 1.18 million shares versus an average volume of 1.08 million shares during last trading session. Its last month’s stock price volatility remained 3.9% which for the week approaches 3.88%. The lowest price the stock reached in the last trading day was $5.39 and compares with the $4.94 52-week low. The stock recovered 9.31% since its low point and has performed 0.93% year-to-date.